A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring
Recruiting
Observational Study
Familial Pancreatic Cancer
Familial Pancreatic Carcinoma
Hereditary Pancreatic Cancer
Hereditary Pancreatitis
Pancreas Cancer
Pancreas Neoplasm
Pancreas Adenocarcinoma
Pancreas Cyst
Pancreatic Neoplasms
Intraductal Papillary Mucinous Neoplasm
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 99
- Sex
- Any
- Study type
- Observational
- Participants needed
- 600 (estimated)
- Sponsor
- Università Vita-Salute San Raffaele · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adult men or women aged ≥18 years at the time of plasma sample collection.
* Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to familial pancreatic cancer or hereditary pancreatic cancer syndrome
* Classification as at increased risk for pan…
Contacts